60岁及以下原发中枢神经系统淋巴瘤患者接受放疗或自体干细胞移植:ANOCEF-GOELAMS组间随机II期PRECIS研究结果
PRECIS研究纳入140例18至60岁未治疗的原发中枢神经系统淋巴瘤患者,诱导化疗后随机接受全脑放疗或自体干细胞移植巩固。两方案均达到预设阈值,2年无进展生存率全脑放疗组63%、自体干细胞移植组87%;全脑放疗后出现认知功能损害,而自体干细胞移植后认知功能保持或改善。
要点
- 全脑放疗与自体干细胞移植作为巩固治疗均达到预设疗效阈值。
- 2年无进展生存率全脑放疗组63%(95%CI 49%至81%),自体干细胞移植组87%(95%CI 77%至98%)。
- 全脑放疗后观察到认知功能损害,自体干细胞移植后认知功能保持或改善。
核心结论
- 全脑放疗和自体干细胞移植是60岁及以下原发中枢神经系统淋巴瘤患者的有效巩固治疗。
- 疗效终点倾向于支持自体干细胞移植组。
- 应考虑每种操作的特有风险。
研究设计与样本
- 非比较性II期随机试验,意向性分析。
- 2008年10月至2014年2月从23家法国中心招募140例18至60岁未治疗的原发中枢神经系统淋巴瘤免疫功能正常患者。
- 诱导化疗为两周期R-MBVP(利妥昔单抗375 mg/m2 第1天,甲氨蝶呤3 g/m2 第1天;第15天,VP16 100 mg/m2 第2天,BCNU 100 mg/m2 第3天,泼尼松60 mg/kg/d 第1至5天)后接两周期R-AraC(利妥昔单抗375 mg/m2 第1天,阿糖胞苷3 g/m2 第1至2天),随后随机接受全脑放疗或自体干细胞移植巩固。
- 自体干细胞移植前强化化疗为塞替派(250 mg/m2/d 第9天;第8天;第7天)、白消安(8 mg/kg 第6天至第4天)和环磷酰胺(60 mg/kg/d 第3天;第2天)。
- 全脑放疗剂量为40 Gy(2 Gy/次)。
主要发现
- 全脑放疗组和自体干细胞移植组2年无进展生存率分别为63%(95%CI 49%至81%)和87%(95%CI 77%至98%)。
- 全脑放疗组和自体干细胞移植组分别记录到1例和5例毒性死亡。
- 全脑放疗后观察到认知功能损害,而自体干细胞移植后认知功能保持或改善。
关键数值与推荐
- 主要终点为2年无进展生存率。
- 认知结果为次要终点。
- 预设阈值:每组前38例患者中至少24例在2年时存活且无病。
- 全脑放疗和自体干细胞移植均达到预设阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 mg/m2 D2, BCNU 100 mg/m2 D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m2 D1, cytarabine 3 g/m2 D1 to D2). Intensive chemotherapy consisted of thiotepa (250 mg/m2/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). WBRT delivered 40 Gy (2 Gy/fraction). The primary end point was 2-year progression-free survival. Cognitive outcome was the main secondary end point. Analysis was intention to treat in a noncomparative phase II trial. RESULTS: Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSION: WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.
引用
- Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019. PMID: 30785830. doi:10.1200/JCO.18.00306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。